TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives
TXMD•Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Income from Cont Ops | $164,000 | ||
| Q2 Operating Expenses | $1.69 mln |
Result drivers
- Licensed product sales - Co said lower sales of licensed products drove decline in Q2 license revenue
Q2 license revenue falls
- US pharmaceutical royalty company's Q2 license revenue declined yr/yr due to lower licensed product sales
- Net income from continuing operations fell compared to prior yr
- Company continues to evaluate strategic alternatives, including possible merger or asset sale
Strategic review and outlook
- Company will recognize a CAD 500,000 milestone payment as revenue in Q3 2026
- TherapeuticsMD continues to evaluate strategic alternatives, including possible mergers or asset sales
- No assurance or timetable for completion of strategic review has been established
